A new paper by Sean Singer, HMS student starting dermatology residency, and Alex S. Keuroghlian, HMS Associate Professor of Psychiatry, describes the potential benefits of Isotretinoin in treating acne related to HRT for transmasculine people. The paper also discusses the current barriers to Isotretinoin access and recommendations for change, including gender-inclusive data collection for the iPLEDGE program and increasing the number of trans-affirming health providers who can prescribe Isotretinoin in order to avoid referals to additional providers.
Abstract: Acne is a common adverse event among trans-masculine people using testosterone as masculinizing hormone therapy. Isotretinoin is the most effective medication for severe recalcitrant acne and, as such, trans-masculine people with severe acne would likely benefit from treatment with this therapy. Incorporation of gender identitybased questions in iPLEDGE registration documentation will increase information about gender-diverse patients taking isotretinoin in the United States and allow better understanding of teratogenicity risks among these patients. An increase in the number of transgender health providers registered as isotretinoin prescribers in iPLEDGE would increase access to this effective medicine and may improve outcomes in these patients.
Published Online: 25 May 2020
The paper can be accessed through PubMed via Harvard.